NEW YORK, NY
Flatiron Health today announced eight abstracts have been accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8.
“Flatiron’s research continues to demonstrate the important applications of real-world data and the insights of real-world evidence,” said Michael Vasconcelles, MD, Chief Medical Officer at Flatiron. “The research abstracts being presented at ASCO 2021 include work illuminating racial disparities in treatment among breast cancer patients, advancing our understanding of the COVID-19 pandemic’s impact on cancer treatment, and matching patients to clinical trials through an AI-based point-of-care tool.”
This year’s accepted abstracts again reflect Flatiron’s many collaborations and partnerships in pursuit of its mission to improve lives by learning from the experience of every cancer patient.
- an investigation of racial disparities in treatment patterns among breast cancer patients, aligned with the 2021 ASCO theme of “Equity: Every Patient. Every Day. Everywhere.”
- a machine-learning tool that can ultimately improve patients’ access to clinical trials by improving the efficiency of patient ascertainment and thereby removing a barrier for practices to take part in studies of rare populations
- a deep learning algorithm that automates the extraction of dates of key clinical events from unstructured chart notes, reducing the need for human curation in real-world data (RWD) research
- leveraging the Flatiron Health-Foundation Medicine Clinico-Genomic Database to understand implications of NGS-defined biomarkers in patients with breast cancer and gastroesophageal cancers
- an illustration of the power of a nationwide RWD network in aggregating clinical information to study treatment patterns and outcomes in patients with Castleman disease, a rare lymphoproliferative disorder
- a description of the evolving impact of the COVID-19 pandemic on cancer treatment.
Flatiron collaborated on the accepted research with: Beth Israel Deaconess Medical Center, Birmingham Hematology Oncology (Alabama Oncology), Cancer Partners of Nebraska, Dana-Farber Cancer Institute, Foundation Medicine, Fox Chase Cancer Center, Massachusetts General Hospital, Moffitt Cancer Center, Penn Medicine, University of Alabama at Birmingham and Yale University.
Full abstracts will be posted at rwe.flatiron.com post-ASCO embargo on June 4.
Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi)
First author: Felipe Batalini (Beth Israel Deaconess Medical Center)
Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease
First author: Aaron B. Cohen (Flatiron Health)
Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC)
First author: Cheryl D. Cho-Phan (Flatiron Health)
ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA)
First author: Samuel J. Klempner (Massachusetts General Hospital)
Extracting non-small cell lung cancer (NSCLC) diagnosis and diagnosis dates from electronic health record (EHR) text using a deep learning algorithm
First author: Alexander S. Rich (Flatiron Health)
Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice
First author: Xiaoliang Wang (Flatiron Health)
Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer
First author: Samuel U. Takvorian (Perelman School of Medicine at the University of Pennsylvania)
An automated EHR-based tool to facilitate patient identification for biomarker-driven trials
First author: Shailendra Lakhanpal (Birmingham Hematology Oncology/Alabama Oncology)